Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Retained Earnings (2023 - 2026)

ArriVent BioPharma has reported Retained Earnings over the past 4 years, most recently at -$270000.0 for Q1 2026.

  • Quarterly results put Retained Earnings at -$270000.0 for Q1 2026, down 1488.24% from a year ago — trailing twelve months through Mar 2026 was -$270000.0 (down 1488.24% YoY), and the annual figure for FY2025 was -$404.6 million, down 69.78%.
  • Retained Earnings reached -$270000.0 in Q1 2026 per AVBP's latest filing, up from -$404.6 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$17000.0 in Q1 2025 and bottomed at -$404.6 million in Q4 2025.
  • Median Retained Earnings over the past 4 years was -$186.2 million (2024), compared with a mean of -$176.0 million.
  • The largest annual shift saw Retained Earnings soared 99.99% in 2025 before it crashed 1488.24% in 2026.
  • Over 4 years, Retained Earnings stood at -$157.8 million in 2023, then plummeted by 50.99% to -$238.3 million in 2024, then tumbled by 69.78% to -$404.6 million in 2025, then soared by 99.93% to -$270000.0 in 2026.
  • Business Quant data shows Retained Earnings for AVBP at -$270000.0 in Q1 2026, -$404.6 million in Q4 2025, and -$369.1 million in Q3 2025.